Key result
Longitudinal increases in circulating amyloid-β42 were independently associated with the development of future mild cognitive impairment (OR 1.089) over 36 months in patients with chronic heart failure.
Why the study?
Chronic HF is associated with cognitive impairment and dementia, and blood-based neurodegenerative biomarkers may support early risk stratification and outcome prediction.
Do longitudinal increases in circulating neurodegenerative biomarkers predict cognitive decline, structural brain changes, and mortality in patients with chronic heart failure?
Cohort (n=104)
No
Do longitudinal increases in circulating neurodegenerative biomarkers predict cognitive decline, structural brain changes, and mortality in patients with chronic heart failure?
Serial measurement of blood neurodegenerative biomarkers, particularly amyloid-β peptides, offers greater prognostic utility than baseline measurement alone for predicting cognitive decline, brain structural deterioration, and mortality in stable heart failure patients.
Answers are grounded in this paper and cite their sources.
Serial Aβ42 monitoring may flag cognitive risk in chronic HF; hypothesis-generating pending prospective trials.
INTRODUCTION: Chronic heart failure (HF) is associated with mild cognitive impairment (MCI), vascular dementia, and Alzheimer's disease. Blood-based neurodegenerative biomarkers may support early risk stratification and outcome prediction in HF. METHODS: In the prospective Cognition.Matters-HF cohort study, serum neurofilament light chain (NfL), glial fibrillary acidic protein, and phosphorylated tau protein-181, as well as plasma amyloid-β peptides (Aβ38, Aβ40, Aβ42) and β-synuclein, were quantified longitudinally over 36 months using ultrasensitive immunoassays and immunoprecipitation mass spectrometry. Cerebral magnetic resonance imaging and standardized domain-specific cognitive testing were performed. Multivariable logistic regression was used to assess associations with future MCI, brain structural changes, and 5-year all-cause mortality. RESULTS: Among 104 patients with chronic HF (10% female, age 64 ± 10 years), all biomarkers except NfL increased significantly over 3 years (P < .05). Median annual percentage changes were 36.6% for phosphorylated tau protein-181, 4.6% for glial fibrillary acidic protein, 2.6% for β-synuclein, 0.6% for Aβ38, 0.5% for Aβ40, and 0.3% for Aβ42. After adjusting for clinical confounders, increases in Aβ38 and Aβ42 independently associated with future MCI, pathological white matter hyperintensity progression (>5% per year), and 5-year mortality (all P < .05). Glial fibrillary acidic protein levels and phosphorylated tau protein-181 trajectories were independently associated with pathological brain atrophy (>0.3% per year). CONCLUSION: In clinically stable patients with chronic HF, longitudinal increases in circulating amyloid-β peptides associated with cognitive decline, structural brain changes, and mortality. Serial biomarker assessment provided stronger prognostic information than baseline measurements alone. Replication in larger cohorts is required.
No takes yet. Share an insight, caveat, or question.
Traub et al. (2026) conducted a cohort in Chronic heart failure (n=104). Longitudinal increases in circulating amyloid-β peptides (e.g., Aβ42) vs. Stable or decreasing biomarker concentrations was evaluated on Future mild cognitive impairment at 36 months (associated with changes in Amyloid-β peptide 42) (OR 1.089, 95% CI 1.019-1.201, p=0.037). Longitudinal increases in circulating amyloid-β42 were independently associated with the development of future mild cognitive impairment (OR 1.089) over 36 months in patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: